Rivaroxaban in clinical practice for stroke prevention in patients with non-valvular atrial fibrillation

Abstract:

Randomised controlled clinical trials are considered the gold standard of research in clinical medicine, but the results of these trials do not always reflect the complexity of everyday treatment. Therefore, a research from clinical practice is being carried out increasingly, better illustrating „real-life“. When it comes to rivaroxaban, a prospective noninterventional observational study XANTUS has confirmed efficacy and favorable safety profile of rivaroxaban in patients with non-valvular atrial fibrillation (AF), as had previously been established in ROCKET AF registration study. The results from retrospective database analyses (American REVISIT-US, German RELIEF), US Department of Defense Postmarketing Safety Surveillance Study (PMSS) as well as from the Danish registries, additionally support these findings and provide complementary data on post-registration use of rivaroxaban in everyday practice. International and local registers, such as GARFIELD-AF, ORBIT-AF and Dresden NOAC registry, indicate an increasing administration of NOAC compared to vitamin K antagonists and the fact that rivaroxaban is a valid anticoagulant option for the use in daily practice in patients with non-valvular AF.

Key words:
atrial fibrillation; clinical practice; rivaroxaban; stroke prevention